Vitamin K2 + D3 by 1 Body — Ingredients, Evidence & Safety

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Vitamin D3: 0.125mg is 1.2× the Tolerable Upper Intake Level (0.1mg)

Label Data

1 Veggie Capsule(s) Serving Size

60 Servings

Vitamin Product Type

50% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin D3

125 mcg (625% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 1.2× (UL: 0.1 mg) 📚 604 studies (Tier A: 16, B: 251)

RDA 0.015mg This product: 0.125mg UL 0.1mg

Vitamin K2

100 mcg

✅ Within RDA (0.8× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 0.1mg

Calcium

210 mg (16% DV)

Bioperine

5 mg

Other Ingredients

Cellulose

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: As a dietary supplement take one (1) veggie capsule twice a day. For best results take 20-30 minutes before a meal with an 8oz. glass of water or as directed by your healthcare professional.

⚠️ Warnings & Precautions

Pregnant or nursing mothers, children under the age of 18, and individuals with a known medical condition should consult a physician before using this or any dietary supplement.

Keep out of the reach of children.

Do not use if seal is damaged or missing.

Caution: Do not exceed recommended dose.

🧪 Formulation Notes

Healthy bone & heart support Blood circulation assistance

100% Vegan friendly

Made with Non-GMO ingredients

Additional Information

Store in a cool, dry place.

Made in USA Third Party Tested

Product Details

UPC / SKU X002MF75EL

DSLD Entry Date 2023-06-22

Product Type Vitamin

Form Capsule

Brand 1 Body

DSLD ID 292767

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation